E-cigarette or vaping product use-associated lung injury (EVALI) masquerading as COVID-19.
BMJ Case Rep
; 14(7)2021 Jul 23.
Article
in English
| MEDLINE | ID: covidwho-1322781
ABSTRACT
SARS-CoV-2, the novel coronavirus causing COVID-19, has caused a global pandemic resulting in over 4 million deaths globally (data current as of 14 July 2021). E-cigarette or vaping product use-associated lung injury (EVALI) is a type of acute lung injury of unclear pathogenesis. The two pathologies present with overlapping clinical symptoms, laboratory values and imaging, making them difficult to distinguish, especially in the setting of a global COVID-19 pandemic. We present the case of a 32-year-old woman treated for COVID-19 despite multiple negative SARS CoV-2 PCR tests and nucleocapsid antibody test. On further investigation, she endorsed use of E-cigarettes and was subsequently diagnosed with EVALI. The patient was treated with oral and intravenous steroids, resulting in significant improvement in her symptoms. This case highlights the challenge of diagnosing rarer aetiologies of respiratory distress during the COVID-19 pandemic.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Lung Injury
/
Electronic Nicotine Delivery Systems
/
Vaping
/
COVID-19
Type of study:
Case report
/
Diagnostic study
/
Etiology study
/
Prognostic study
Limits:
Adult
/
Female
/
Humans
Language:
English
Year:
2021
Document Type:
Article
Affiliation country:
Bcr-2021-243885
Similar
MEDLINE
...
LILACS
LIS